Multi-Receptor Antagonist Compounds for Prostaglandin-Mediated Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by prostaglandin receptors, such as inflammation and pain, often come with side effects like gastrointestinal toxicity and asthma exacerbation, and lack specificity in targeting individual receptor subtypes.
Innovation Solution
Development of compounds with specific structures, like 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid, which act as selective antagonists or agonists for DP1, FP, EP1, EP4, and TP receptors, reducing side effects and enhancing efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NSAIDs are used to treat inflammation and pain, then anti-inflammatory and analgesic effects are achieved, but gastrointestinal toxicity and renal side effects occur
Solution Approach 1:
The patent segments the prostaglandin receptor system into multiple subtype receptors (EP1, EP2, EP3, EP4, DP1, FP, TP) and develops selective antagonists for each subtype. This allows targeted inhibition of specific prostaglandin pathways responsible for inflammation and pain while sparing pathways involved in gastrointestinal protection and renal function, thereby resolving the contradiction between anti-inflammatory efficacy and gastrointestinal safety
Solution Approach 2:
The patent applies local quality by creating receptors with subtype-specific binding properties. Each prostaglandin receptor subtype (EP1, EP2, EP3, EP4, DP1, FP, TP) has distinct tissue distribution and functional characteristics, allowing selective pharmacological intervention in inflammatory sites while preserving normal physiological functions in other tissues
2Reliability
If selective EP1 receptor antagonists are used to reduce pain and inflammation, then analgesic effects are improved, but the ability to treat multiple prostaglandin-mediated conditions is limited
Solution Approach 1:
The patent develops a universal approach by creating antagonists that can selectively target multiple prostaglandin receptor subtypes (EP1, EP2, EP3, EP4, DP1, FP, TP) within a single therapeutic agent. This multi-functional capability allows treatment of diverse prostaglandin-mediated conditions including inflammation, pain, asthma, and renal dysfunction through a unified mechanism of action
3Object-affected harmful factors
If TP receptor antagonists are used to treat asthma, then bronchoconstriction is reduced, but platelet aggregation and vascular constriction effects may be affected
Solution Approach 1:
The patent applies local quality by exploiting the tissue-specific distribution and functional characteristics of the TP receptor. By developing selective TP receptor antagonists, the treatment can target bronchial smooth muscle relaxation while preserving platelet aggregation and vascular constriction functions where TP receptors play critical physiological roles
Data Source
AI summary
The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formulaWherein R1, R2, R3, R4, R5, R6, X, W, X and Y are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions.